Boehringer Ingelheim Biopharmaceuticals GmbH
Biberach an der Riß, Germany
Program data pending ClinicalTrials.gov matching
—
Not Assessed
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesBiologics/mAb, Recombinant Proteins, Biosimilars
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press1 articles
Manufacturing site information being gathered
Modalities: Biologics/mAb, Recombinant Proteins, Biosimilars
Capacity assessment: 55.0/100
Recent News 1 articles
Antibody Contract Manufacturing Market to be Worth USD 22.0 billion by 2032 - Straits Research
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: